Patient No. | Age | Site of Colorectal Cancer | Family History | Bethesda Criteria Met | MMR Protein Deficiency by IHC | Genomic Sequencing | Nucleotide Change | Amino Acid Change | Mechanism | Stage | Adjuvant Treatment | Survival and follow-up (as of Jan 2017) |
---|---|---|---|---|---|---|---|---|---|---|---|---|
139 | 28 | Sigmoid | Maternal grandfather had resected colon mass at age 40 | Yes #1 | MSH6 | MSH6 | c.4002-2A>Ga | n/a | Intervening sequence, RNA processing | T3Â N0 Stage IIA | Clinical trial E5202 | 85Â m alive |
170 | 33 | Sigmoid | Father colon cancer at age < 40 y; Maternal grandmother colon cancer at age < 40 | Yes #1, #4, #5 | Not done | EPCAM MLH1 MSH2 | 3′ terminal deletion c.1100C > A deletion exon 1 | Thr367 Asn | Large deletion of 3′ EPCAM and 5′ of MSH2 | T4bN0 Stage IIC | Oxaliplatin + Xeloda | 65 m alive |
175 | 43 | Transverse | Father died from gastric cancer, diagnosed at 53 | Yes #1 | MSH2, MSH6 | MSH2 | c.1386 + 2 T>Cb | n/a | Intervening sequence, RNA processing | T4aN1b Stage IIIB | Oxaliplatin 5-Fu Leucovorin | 53 m (33 m since last f/u) |
200 | 47 | Sigmoid | Mother colon cancer at age 71 | Yes #1 | MSH6 | MSH6 | c.1882delT | Trp628 Glysfsc7 | Premature truncation of the amino acid at position 634 | T3Â N0 Stage IIA | None | 22Â m alive |
226 | 71 | Ascending | Son colon cancer at age 47 | Yes #4 | MSH6 | MSH6 | c.1882delT | Trp628 Glysfsc7 | Premature truncation of the amino acid at position 634 | T3Â N0 Stage IIA | None | 32Â m alive |
275 | 42 | Descending | Father colon cancer at age 35 | Yes #1, #4 | MLH1, PMS2 | MLH1 | c.677G > Ac | Arg226 Gln | Skipping of exon 8 | T3 N0 Stage IIA | None | 41 m (32 m since last f/u) Recurrence April 2014 |